We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?
Read MoreHide Full Article
AVEO Pharmaceuticals, Inc. is expected to report fourth-quarter 2017 results on Mar 28.
Last quarter, AVEO delivered a positive surprise of 60%.
The company significantly outperformed the industry last year. The stock surged 207.1% against a decline of 2.8% for the industry.
Let’s see how things are shaping up for this quarter.
Factors at Play
In November 2017, AVEO launched Fotivda in Europe starting with Germany, making the drug its first commercial product. The company will receive double-digit royalty payments from EUSA Pharma on net sales of the drug in Europe. However, the impact on the top line remains to be seen.
In August 2017, the European Commission approved Fotivda (tivozanib) for treating first-line treatment for renal cell carcinoma (“RCC”) in adults. The drug has demonstrated superiority over Bayer’s Nexavar in treating RCC.
In October 2017, AVEO announced results of a pre-planned futility analysis of phase III TIVO-3 study comparing Fotivda to Bayer’s Nexavar as treatment for patients with refractory advanced RCC. Based on the results, the company will continue the study unmodified. The data from this study along with previously completed TIVO-1 study will support the regulatory application for approval in the United States.
In December 2017, the company announced completion of enrollment in phase II portion of phase I/II TiNivo study evaluating Fotivda in combination with Bristol-Myers’ (BMY - Free Report) Opdivo in RCC.
Apart from Fotivda, AVEO is also developing ficlatuzumab in combination with Lilly’s Erbitux in a phase II study for treating metastatic head and neck squamous cell carcinoma. Another phase Ib study is evaluating the candidate in combination with Nab-paclitaxel and Gemcitabine in treatment-naive pancreatic cancer. These studies were initiated during the quarter.
We expect research & development expenses to increase in the quarter due to initiation of ficlatuzumab studies and continuation of TIVO-3 study.
Investor focus will likely remain on updates related to Fotivda’s launch and progress of ficlatuzumab.
Surprise History
AVEO’s performance over the last four quarters has been mixed with the company surpassing expectations thrice and missing once with an average positive surprise of 16.37%.
Earnings Whispers
Our proven model does not conclusively show that AVEO is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Zacks ESP: Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00% with both pegged at a loss of 3 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Although AVEO’s Zacks Rank #3 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Here are a couple of health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Gemphire Therapeutics is expected to release results on Mar 21. The company has an Earnings ESP of +24.74% and a Zacks Rank #2.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?
AVEO Pharmaceuticals, Inc. is expected to report fourth-quarter 2017 results on Mar 28.
Last quarter, AVEO delivered a positive surprise of 60%.
The company significantly outperformed the industry last year. The stock surged 207.1% against a decline of 2.8% for the industry.
Let’s see how things are shaping up for this quarter.
Factors at Play
In November 2017, AVEO launched Fotivda in Europe starting with Germany, making the drug its first commercial product. The company will receive double-digit royalty payments from EUSA Pharma on net sales of the drug in Europe. However, the impact on the top line remains to be seen.
In August 2017, the European Commission approved Fotivda (tivozanib) for treating first-line treatment for renal cell carcinoma (“RCC”) in adults. The drug has demonstrated superiority over Bayer’s Nexavar in treating RCC.
In October 2017, AVEO announced results of a pre-planned futility analysis of phase III TIVO-3 study comparing Fotivda to Bayer’s Nexavar as treatment for patients with refractory advanced RCC. Based on the results, the company will continue the study unmodified. The data from this study along with previously completed TIVO-1 study will support the regulatory application for approval in the United States.
In December 2017, the company announced completion of enrollment in phase II portion of phase I/II TiNivo study evaluating Fotivda in combination with Bristol-Myers’ (BMY - Free Report) Opdivo in RCC.
Apart from Fotivda, AVEO is also developing ficlatuzumab in combination with Lilly’s Erbitux in a phase II study for treating metastatic head and neck squamous cell carcinoma. Another phase Ib study is evaluating the candidate in combination with Nab-paclitaxel and Gemcitabine in treatment-naive pancreatic cancer. These studies were initiated during the quarter.
We expect research & development expenses to increase in the quarter due to initiation of ficlatuzumab studies and continuation of TIVO-3 study.
Investor focus will likely remain on updates related to Fotivda’s launch and progress of ficlatuzumab.
Surprise History
AVEO’s performance over the last four quarters has been mixed with the company surpassing expectations thrice and missing once with an average positive surprise of 16.37%.
Earnings Whispers
Our proven model does not conclusively show that AVEO is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Zacks ESP: Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00% with both pegged at a loss of 3 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Although AVEO’s Zacks Rank #3 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
AVEO Pharmaceuticals, Inc. Price and Consensus
AVEO Pharmaceuticals, Inc. Price and Consensus | AVEO Pharmaceuticals, Inc. Quote
Stocks That Warrant a Look
Here are a couple of health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Celldex Therapeutics, Inc. (CLDX - Free Report) is scheduled to release results on Mar 7. The company has an Earnings ESP of +18.28% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Gemphire Therapeutics is expected to release results on Mar 21. The company has an Earnings ESP of +24.74% and a Zacks Rank #2.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>